Crossbow Therapeutics
About
What does Crossbow Therapeutics do?
Crossbow Therapeutics is a biotechnology company focused on developing novel T-cell receptor (TCR)-mimetic antibody therapies for the treatment of cancer. Their approach aims to leverage the specificity of T-cell receptors to target cancer cells with high precision. The company recently announced a $77 million Series B financing round to advance its pipeline.
What is Crossbow Therapeutics's revenue?
StartupHub estimates Crossbow Therapeutics's annual revenue at $5.1M (range $3.0M to $17.7M, 69% confidence), based on comparable companies in the sector.
What is Crossbow Therapeutics's valuation?
StartupHub estimates Crossbow Therapeutics's effective valuation at $618.0M (range $392.5M to $942.0M, 23% confidence), based on comparable companies in the sector.
How much funding has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised a total of $157M in funding. The most recent round on record is Series B.
Where is Crossbow Therapeutics headquartered?
Crossbow Therapeutics is headquartered in Cambridge, United States.
When was Crossbow Therapeutics founded?
Crossbow Therapeutics was founded in 2021.
What industry does Crossbow Therapeutics operate in?
Crossbow Therapeutics operates in Biotechnology, Pharmaceuticals, Cancer, Immunotherapy, Oncology.
How many employees does Crossbow Therapeutics have?
Crossbow Therapeutics has approximately 40 people on record.
No comments yet. Be the first to share your take.